- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Christine Simmon Discusses the Purple Book, Patents, and Biosimilars
Christine Simmon discussed the Purple Book and how it will affect biosimilar makers and illuminate patent hurdles at the recent FDA/Federal Trade Commission workshop on anticompetitive practices.
Christine Simmon, JD, is the senior vice president of policy & strategic alliances of the Association for Accessible Medicines (AAM) and the executive director of AAM’s Biosimilars Council.
Transcript:
Tell us about the Purple Book and what it will mean for biosimilar makers and patent thickets.
The Purple Book is an FDA version of the current Orange Book. And so what it does is it provides sort of a cheat sheet for biosimilar and other people interested in biosimilar manufacturing and uptake to see what the reference product biologics are and whether or not there are biosimilars currently approved for those products and sort of what we can expect. It's a helpful tool that the FDA has recently made more helpful by rendering it searchable electronically. So, that's a positive development. I think that the Purple Book still suffers from not having mandatory listings of all the patents related to the biologic reference product. That is something that the agency, the FDA, cannot impose by itself, and so legislation would be required for that. And fortunately, there is legislation introduced by Senator Susan Collins [R-ME] to require that the Purple Book include all the patents for a biologic reference product. That would go a long way for biosimilar manufacturers looking to get into those products.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
